Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 762 citations

Severe acute interstitial pneumonia and gefitinib

Akira Inoue, Yasuo Saijo, Makoto Maemondo et al. · The Lancet · 2003 · 452 citations

Antibiotics, Acute Care, Interstitial Pneumonia +3

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Masahiko Ando, Isamu Okamoto, Nobuyuki Yamamoto et al. · Journal of Clinical Oncology · 2006 · 356 citations

Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis

Spencer B. Gibson, S. Sean Tu, Ryan Oyer et al. · Journal of Biological Chemistry · 1999 · 249 citations · Full text

Tumor Biology, Fas-induced Apoptosis, Death Receptor-induced Apoptosis +14

EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats

Vicente E. Torres, William E. Sweeney, Xiaofang Wang et al. · Kidney International · 2003 · 135 citations · Full text

Signal Transduction, Signaling Pathway, Growth Hormone +6